济因生物科技有限公司是一家研发型生物技术公司，致力于肿瘤基因与细胞治疗新疗法的研究，希望为癌症治疗提供最有前景的通用型疗法解决方案。 核心研发团队在细胞治疗和基因治疗领域的拥有多年的先进经验，依赖于自身的技术能力，公司已搭建了体内CAR-T技术平台和iPS重编程及定向分化等平台。公司正积极推动多个细胞产品进入临床研究。

Genocury Biotech Ltd. is a R&D biotechnology corporation, which commits to the research of cell and gene therapies(CGT) targeting various tumor, we also hope to offer the most promising geneeral treatment therapy options. The R&D team of Genocury are all experienced personnel in the field of CGT. Independently, they has already built an in-vivo CAR-T technology platform, and iPS reprogramming and directional differentiation platform. Right now, Genocury is actively promoting multiple cell products into clinical studies.